Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Spotify Technology (SPOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Spotify Technology — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224 (market cap $29.60B), while Spotify Technology trades at $489.6 (market cap $103.00B). The key difference: Spotify Technology is far larger — about 3.5× Alnylam Pharmaceuticals, Inc.'s market cap, and Spotify Technology is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | SPOT | |
|---|---|---|
Market Cap | $29.60B | $103.00B |
Sector | Health | Media |
52-Week High | $491.22 | $738.53 |
52-Week Low | $205.48 | $412.75 |
Enterprise Value | $27.56B | $92.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Spotify (SPOT) trades at $486.44, down 4.96% over 24 hours, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong revenue growth to $17.19B in 2025 and net income of $2.21B, with a record 300 million Premium subscribers in Q2 2026. Recent news highlights Spotify's initiative to label AI-generated artists for transparency, reflecting proactive content management.
The outlook remains positive with a consensus price target of $598.20, implying significant upside. Key risks include rising marketing and AI costs impacting margins, as seen in the Q2 2026 earnings miss. Investor sentiment is buoyed by subscriber growth and monetization efforts, but execution on cost control will be critical for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Spotify Technology
Spotify Technology S.A. provides music streaming services. The Company offers commercial-free music and ad-supported services to subscribers. Spotify Technology serves clients worldwide.
Read more on SPOT →
